Динамика массы тела у пациентас пролактинсекретирующей аденомой гипофизадо и после лечения каберголином

1. Дедов И.И., Мельниченко Г.А. Персистирующая галакторея-аменорея - М.: Медицина, 1985. - 253 с.

2. Романцова Т.И. Особенности клинической симптоматики, диагностики и лечения синдрома гиперпролактинемии у женщин. Автореферат. Дис. докт. мед.наук. -М. 2001.

3. Baptista Т., Lacruz A., Meza Т., Contreras Q., Delgado C., Mejas M.A., Hernаndez L. Antipsychotic drugs and obesity: is prolactin involved? // Can J Psychiatry. - 2001. -Vol. 46. N 9. - P. 829-834.

4. Brandebourg Т., Hugo E. Adipocyte prolactin: regulation of release and putative functions. Diabetes, Obesity and Metabolism, 9, 2007, 464-476.

5. Burstyn P.G., Horrobin D.F., Muiruri K. Effects of a high fat diet and of intravenous infusions of cholesterol on arterial pressure in rabbits. Br J Exp Pathol 1972 Jun;53(3): 258-64.

6. Cincotta A. H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects Diabetes Care 1996, 19, 667-70.

7. Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N EngfJ Med 2003; 349: 2023-33.

8. Colao A., Gillam M.P., Molitch M.E., Lombardi G. Advances in the Treatment of Prolactinomas Endocrine Reviews 2006, 27J5): 485-534.

9. Gillam M.P., Middler S., Freed D.J., Molitch ME 2002. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451.

10. Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels Clin Endocrinol 1998, 48, 547-53.

11. Herring N., Szmigielski C. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology (2009) 70, 104-108.

12. Kamath V., Jones C.N., Yip J.C. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women Diabetes Care 1997, 20, 1697-701.

13. Keshavan G. Bina, Anthony H. Cincotta. Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob Mice. Neuroendocrinology 2000; 71: 68-78.

14. Korner J. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obesity Research (2003) 11, 31 1-312; doi: 10.1038/oby. 2003.46.

15. Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology. 2001 Nov;142(11):4880-90.

16. McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996, 137:5723-5726.

17. Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. // Clin Endocrinol (Oxf). -1982.- Vol. 16. N. 4. - P. 383-390.

18. Pijl H., Ohashi S., Matsuda M. Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23,1154-1161.

19. Prior J.C., Cox T.A., Fairholm D., Kostashuk E., Nugent R. 1987 Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391-394.

20. Weaver J.U., Noonan K., Kopelman P.G., Coste M. Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 1990 May; 32(5): 641-6.

21. Zamorano P.L. et al. 1997 Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat. Neuroendocrinology 65: 223-228.